MCID: HPT015
MIFTS: 52

Hepatitis D

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases

Aliases & Classifications for Hepatitis D

MalaCards integrated aliases for Hepatitis D:

Name: Hepatitis D 12 77 54 45 15 17
Delta Hepatitis 12 54
Hepatitis Delta 60 56
Hepatitis D Infection 74
Hepatitis D Virus 60
Hdv 60

Classifications:



External Ids:

Disease Ontology 12 DOID:2047
MeSH 45 D003699
ICD10 via Orphanet 35 B17.0
UMLS via Orphanet 75 C0011226
Orphanet 60 ORPHA402823
UMLS 74 C0011226

Summaries for Hepatitis D

Disease Ontology : 12 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis delta virus, which is an incomplete virus that requires the helper function of Hepatitis B virus to replicate and only occurs among people who are infected with the Hepatitis B virus. The infection has symptom fatigue, has symptom lethargy, has symptom anorexia, has symptom nausea, has symptom jaundice, has symptom clay-colored stools, has symptom dark urine, has symptom changes in personality, has symptom disturbances in sleep, has symptom confusion, has symptom abnormal behavior, has symptom somnolence, and has symptom coma.

MalaCards based summary : Hepatitis D, also known as delta hepatitis, is related to hepatitis and hepatitis b, and has symptoms including fatigue, jaundice and anorexia. An important gene associated with Hepatitis D is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Paroxetine Pathway, Pharmacokinetics and Statin Pathway - Generalized, Pharmacokinetics. The drugs Peginterferon alfa-2b and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include liver, b cells and t cells.

Wikipedia : 77 Hepatitis D (hepatitis delta) is a disease caused by the hepatitis D virus (HDV), a small spherical... more...

Related Diseases for Hepatitis D

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Hepatitis D via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.0 F2 GPT IFNA2
2 hepatitis b 30.6 F2 GPT IFNA2
3 viral hepatitis 29.6 F2 GPT IFNA2
4 drug-induced hepatitis 29.5 CYP2C9 CYP2D6 IFNL3
5 hepatitis e 29.3 F2 GPT
6 hepatitis a 29.2 F2 GPT
7 porphyria, acute hepatic 11.2
8 serotonin syndrome 10.1 CYP2D6 IFNA2
9 hepatitis c 10.1
10 sulfonamide allergy 10.1 CYP2C9 CYP2D6
11 hepatocellular carcinoma 10.1
12 hepatitis c virus 10.1
13 liver disease 10.1
14 multiple chemical sensitivity 10.1 CYP2C9 CYP2D6
15 cryoglobulinemia 10.0 IFNA2 IFNL3
16 hepatoportal sclerosis 10.0 F2 GPT
17 porphyria 10.0
18 hepatic tuberculosis 10.0 F2 GPT
19 kwashiorkor 10.0 F2 GPT
20 hemangioma of liver 10.0 F2 IFNA2
21 hepatic coma 10.0 F2 GPT
22 giant hemangioma 10.0 F2 IFNA2
23 infantile liver failure syndrome 1 10.0 F2 GPT
24 nonalcoholic steatohepatitis 10.0 F2 GPT
25 choledocholithiasis 10.0 F2 GPT
26 analbuminemia 10.0 F2 GPT
27 acute liver failure 9.9 F2 GPT
28 bile duct disease 9.9 F2 GPT
29 cholecystitis 9.9 F2 GPT
30 obstructive jaundice 9.9 F2 GPT
31 hepatic encephalopathy 9.9 F2 GPT
32 alcoholic hepatitis 9.8 F2 GPT
33 deafness-infertility syndrome 9.8
34 desmoplastic infantile ganglioglioma 9.8
35 wilson disease 9.8 F2 GPT
36 portal hypertension 9.8 F2 GPT
37 bilirubin metabolic disorder 9.8 F2 GPT SLC35A2
38 autoimmune hepatitis 9.7 CYP2D6 F2 GPT
39 liver cirrhosis 9.7
40 cholangitis 9.7 F2 GPT
41 coproporphyria, hereditary 9.7
42 porphyria cutanea tarda 9.7
43 sjogren syndrome 9.7
44 human immunodeficiency virus type 1 9.7
45 bestrophinopathy, autosomal recessive 9.7
46 ischemic heart disease 9.7
47 leukemia 9.7
48 brucellosis 9.7
49 nephrotic syndrome 9.7
50 arteriosclerosis 9.7

Graphical network of the top 20 diseases related to Hepatitis D:



Diseases related to Hepatitis D

Symptoms & Phenotypes for Hepatitis D

Symptoms:

12 (show all 13)
  • fatigue
  • jaundice
  • anorexia
  • confusion
  • coma
  • lethargy
  • nausea
  • somnolence
  • abnormal behavior
  • clay-colored stools
  • dark urine
  • changes in personality
  • disturbances in sleep

Drugs & Therapeutics for Hepatitis D

Drugs for Hepatitis D (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 4,Phase 3 215647-85-1, 99210-65-8
2
Ribavirin Approved Phase 4,Phase 2,Phase 1 36791-04-5 37542
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 5284616 6436030
4
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
5
Mycophenolic acid Approved Phase 4 24280-93-1 446541
6
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
8 Interferon alpha-2 Phase 4,Phase 3,Phase 2,Phase 1
9 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
10 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1
11 Antimetabolites Phase 4,Phase 2,Phase 1
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
13 interferons Phase 4,Phase 3,Phase 2,Phase 1
14 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Vaccines Phase 4
16 Antibiotics, Antitubercular Phase 4
17 Anti-Bacterial Agents Phase 4
18 Antitubercular Agents Phase 4
19 Immunosuppressive Agents Phase 4
20 Antifungal Agents Phase 4
21 Liver Extracts Phase 4,Phase 2
22
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
23
Tenofovir Approved, Experimental, Investigational Phase 3,Phase 2 147127-20-6 464205
24
Ritonavir Approved, Investigational Phase 3,Phase 2,Phase 1 155213-67-5 392622
25
Lonafarnib Investigational Phase 3,Phase 2 193275-84-2 148195
26 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
27 Anti-HIV Agents Phase 3,Phase 2,Phase 1
28 Anti-Retroviral Agents Phase 3,Phase 2,Phase 1
29 Reverse Transcriptase Inhibitors Phase 3,Phase 2
30 Cytochrome P-450 CYP3A Inhibitors Phase 3,Phase 2,Phase 1
31 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2,Phase 1
32 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1
33
protease inhibitors Phase 3,Phase 2,Phase 1
34
Ezetimibe Approved Phase 2 163222-33-1 150311
35
Lamivudine Approved, Investigational Phase 2 134678-17-4 60825
36
Entecavir Approved, Investigational Phase 2 142217-69-4 153941
37
Promethazine Approved, Investigational Phase 2 60-87-7 4927
38
Histamine Approved, Investigational Phase 2 51-45-6 774
39
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
40
Cetirizine Approved Phase 2 83881-51-0 2678
41
Coal tar Approved Phase 2 8007-45-2
42
Hydroxyzine Approved Phase 2 68-88-2 3658
43 Anticholesteremic Agents Phase 2
44 Lipid Regulating Agents Phase 2
45 Hypolipidemic Agents Phase 2
46 Adjuvants, Immunologic Phase 2
47
Chlorpheniramine Phase 2 113-92-8, 132-22-9 2725
48 Histamine H1 Antagonists Phase 2
49 Histamine Antagonists Phase 2
50 Neurotransmitter Agents Phase 2

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin
2 Improved Prevention of Perinatal Hepatitis B Transmission Unknown status NCT01133184 Phase 4
3 Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) Completed NCT01134952 Phase 4 Mycophenolate to sirolimus switch
4 A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) Completed NCT02732639 Phase 3 Pegylated Interferon (PEG-IFN) alfa-2a
5 A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D. Completed NCT01088659 Phase 3 peginterferon alfa-2a [Pegasys];placebo;tenofovir
6 Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) Completed NCT00686790 Phase 3
7 Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a Recruiting NCT03719313 Phase 3 Lonafarnib;Ritonavir;PEG IFN-alfa-2a;Placebo Lonafarnib;Placebo Ritonavir
8 Phase 3 Study of Bulevirtide in Patients With CHD Not yet recruiting NCT03852719 Phase 3 Bulevirtide
9 Ezetimibe for Patients With Chronic Hepatitis D Unknown status NCT03099278 Phase 2 Ezetimibe
10 Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D Unknown status NCT03105310 Phase 2 Pegylated interferon alfa;Ezetimibe
11 A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D Completed NCT03546621 Phase 2 Myrcludex B;Myrcludex-B;Myrcludex-B;Tenofovir
12 Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir Completed NCT02511431 Phase 2 Lonafarnib;Ritonavir
13 Lonafarnib for Chronic Hepatitis D Completed NCT01495585 Phase 2 Lonafarnib
14 A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD) Completed NCT02731131 Phase 2 Peginterferon alfa-2a;Ribavirin
15 Pegylated Interferon to Treat Chronic Hepatitis D Completed NCT00023322 Phase 2 Peginterferon Alpha-2a
16 HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis Completed NCT00932971 Phase 2 PEG-IFN alfa-2a, Tenofovir;PEG-IFN alfa-2a, placebo
17 A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection Completed NCT02765802 Phase 2 Lambda
18 REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection Completed NCT02233075 Phase 2 REP 2139-Ca + Pegasys (TM)
19 Lonafarnib With and Without Ritonavir in HDV (LOWR-1) Completed NCT02430181 Phase 2 lonafarnib;PEG IFN-a;Ritonavir
20 Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection Completed NCT02637999 Phase 1, Phase 2 PEG IFN alfa-2a;Myrcludex B
21 Lonafarnib With Ritonavir in HDV (LOWR-2) Completed NCT02430194 Phase 2 lonafarnib;Ritonavir;PEG IFN-a
22 Titrating-Dose of Lonafarnib in Combination With Ritonavir Completed NCT02527707 Phase 2 lonafarnib;Ritonavir
23 Lamivudine for Chronic Hepatitis B Completed NCT00001457 Phase 2 Lamivudine
24 Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon Recruiting NCT03600714 Phase 2 Peg-interferon lambda;Lonafarnib;Ritonavir
25 Phase 2b Study of Bulevirtide (With Peginterferon Alfa-2a) in Patients With CHD Not yet recruiting NCT03852433 Phase 2 Bulevirtide;Peginterferon Alfa-2a
26 A Study of Lonafarnib With or Without Ritonavir in Patients With HDV Not yet recruiting NCT02968641 Phase 2 Lonafarnib;Ritonavir
27 Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) Terminated NCT02577029 Phase 2 ARC-520;entecavir;tenofovir disoproxil;antihistamine
28 Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment Completed NCT02259855 Phase 1 Tipranavir;Ritonavir;Pegylated interferon;Ribavirin
29 Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV) Terminated NCT01316185 Phase 1 EBP921
30 Mother-to-child Hepatitis D Transmission Completed NCT02044055
31 Hepatitis Delta Infections in Hemophiliacs Completed NCT00005305
32 Delta Hepatitis and Liver Disease in Hemophiliacs Completed NCT00005304
33 The Hepatitis Delta International Network Recruiting NCT02375906
34 Evaluation of Patients With Liver Disease Recruiting NCT00001971
35 A Long Term Follow-up Study of Patients From the REP 301 Protocol Active, not recruiting NCT02876419
36 Liver Fibrosis in Zambian HIV-HBV Co-infected Patients Active, not recruiting NCT02344680 Anti-HIV Agents
37 Chronic Hepatitis B Virus Infection in Zambia Active, not recruiting NCT03158818
38 Epidemiology of Hepatitis B, C and Delta in Reunion Island Not yet recruiting NCT03362866
39 An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a) Terminated NCT01861444

Search NIH Clinical Center for Hepatitis D

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: hepatitis d

Genetic Tests for Hepatitis D

Anatomical Context for Hepatitis D

MalaCards organs/tissues related to Hepatitis D:

42
Liver, B Cells, T Cells, Testes, Thyroid, Skin, Heart

The Foundational Model of Anatomy Ontology organs/tissues related to Hepatitis D:

20
Liver

Publications for Hepatitis D

Articles related to Hepatitis D:

(show top 50) (show all 591)
# Title Authors Year
1
Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. ( 31068585 )
2019
2
Hepatitis D: not a rare disease anymore: global update for 2017-2018. ( 30967414 )
2019
3
Hepatitis D virus infection in patients with hepatitis B virus occult infection. ( 30920483 )
2019
4
Hepatitis D reactivation in a patient with metastatic renal cell carcinoma receiving sunitinib therapy. ( 30935288 )
2019
5
Early Multiphasic HBV Infection Initiation Kinetics Is Not Clone-Specific and Is Not Affected by Hepatitis D Virus (HDV) Infection. ( 30875937 )
2019
6
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. ( 30833068 )
2019
7
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. ( 30793345 )
2019
8
Genetic diversity of hepatitis D virus genotype 1 in Europe allows classification into subtypes. ( 30801877 )
2019
9
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level. ( 30768983 )
2019
10
The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. ( 30695096 )
2019
11
Hepatitis D - how is the fight against this foe going? ( 30698044 )
2019
12
Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia. ( 30661282 )
2019
13
Hepatitis D Virus-Specific CD8+ T Cells Have a Memory-Like Phenotype Associated With Viral Immune Escape in Patients With Chronic Hepatitis D Virus Infection. ( 30664876 )
2019
14
Prevalence of Hepatitis B and Hepatitis D Virus Infections in the United States, 2011-2016. ( 30605508 )
2019
15
Pathogenesis of and New Therapies for Hepatitis D. ( 30342879 )
2019
16
Small hepatitis delta antigen selectively binds to target mRNA in hepatic cells: a potential mechanism by which hepatitis D virus downregulates glutathione S-transferase P1 and induces liver injury and hepatocarcinogenesis. ( 30153423 )
2019
17
Hepatitis D infection should be taken in mind while evaluating neonatal outcomes related to maternal hepatitis B infection. ( 28854842 )
2019
18
Hepatitis D virus infection among hepatitis B virus surface antigen positive individuals in Upper Egypt: Prevalence and clinical features. ( 30833193 )
2018
19
A Divergent Hepatitis D-Like Agent in Birds. ( 30562970 )
2018
20
Hepatitis D prevalence: problems with extrapolation to global population estimates. ( 30567743 )
2018
21
Delta hepatitis in resolved hepatitis B. ( 30395014 )
2018
22
Devil hepatitis D: an orphan disease or largely underdiagnosed? ( 30368454 )
2018
23
The Epidemiology of Hepatitis D Virus in North Africa: A Systematic Review and Meta-Analysis. ( 30356409 )
2018
24
Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. ( 29775812 )
2018
25
Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults. ( 29698488 )
2018
26
Prevalence of Hepatitis B virus and Hepatitis D virus Coinfection in Western Burkina Faso and molecular characterization of the detected virus strains. ( 29432880 )
2018
27
A comprehensive bioinformatic analysis of hepatitis D virus full-length genomes. ( 29406571 )
2018
28
Targeting Hepatitis D. ( 29471567 )
2018
29
Hepatitis D virus replication is sensed by MDA5 and induces IFN-β/λ responses in hepatocytes. ( 29524530 )
2018
30
Hepatitis D diagnostics:Utilization and testing in the United States. ( 29596839 )
2018
31
Clinical and laboratory characteristics of hepatitis d in Republic of Sakha (Yakutia). ( 29602929 )
2018
32
Hepatitis D infection in Brazil: Prevalence and geographical distribution of anti-Delta antibody. ( 29663457 )
2018
33
Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia. ( 29761607 )
2018
34
Hepatitis D Viremia Among Injection Drug Users in San Francisco. ( 29800369 )
2018
35
Epidemiology and patient characteristics of hepatitis D virus infection in the West of Scotland 2011-2016. ( 29851188 )
2018
36
Molecular Signature and Mechanisms of Hepatitis D Virus-Associated Hepatocellular Carcinoma. ( 29858376 )
2018
37
Hepatitis D virus infection in Kermanshah, west of Iran: seroprevalence and viremic infections. ( 29910856 )
2018
38
A new dual-targeting real-time RT-PCR assay for hepatitis D virus RNA detection. ( 29941366 )
2018
39
Current and Future Management of Chronic Hepatitis D. ( 30166948 )
2018
40
Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil. ( 30192887 )
2018
41
Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. ( 30228220 )
2018
42
Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country. ( 28834623 )
2018
43
Epidemiological data for hepatitis D in Africa. ( 29241610 )
2018
44
Epidemiological data for hepatitis D in Africa. ( 29241611 )
2018
45
Epidemiological data for hepatitis D in Africa - Authors' reply. ( 29241612 )
2018
46
Tat-enhanced delivery of the C terminus of HDAg-L inhibits assembly and secretion of hepatitis D virus. ( 29247673 )
2018
47
Are immunoglobulins against the HBsAg still needed in liver transplantation for hepatitis D? ( 29356031 )
2018
48
Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. ( 29152762 )
2018
49
Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. ( 29425306 )
2018
50
Prevalence of Hepatitis D Among Patients with Hepatitis B Viral Infection Attending a Tertiary Care Centre of Nepal. ( 29453472 )
2017

Variations for Hepatitis D

Expression for Hepatitis D

Search GEO for disease gene expression data for Hepatitis D.

Pathways for Hepatitis D

Pathways related to Hepatitis D according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.5 CYP2C9 CYP2D6
2
Show member pathways
11.46 CYP2C9 CYP2D6
3
Show member pathways
11.13 CYP2C9 CYP2D6
4 10.96 CYP2C9 F2
5 10.79 IFNA2 IFNL3
6
Show member pathways
10.55 CYP2C9 CYP2D6
7
Show member pathways
9.98 IFNA2 IFNL3

GO Terms for Hepatitis D

Biological processes related to Hepatitis D according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.61 F2 IFNA2 IFNL3
2 xenobiotic metabolic process GO:0006805 9.46 CYP2C9 CYP2D6
3 drug metabolic process GO:0017144 9.4 CYP2C9 CYP2D6
4 exogenous drug catabolic process GO:0042738 9.37 CYP2C9 CYP2D6
5 organic acid metabolic process GO:0006082 9.32 CYP2C9 CYP2D6
6 long-chain fatty acid biosynthetic process GO:0042759 9.26 CYP2C9 CYP2D6
7 oxidative demethylation GO:0070989 9.16 CYP2C9 CYP2D6
8 drug catabolic process GO:0042737 8.96 CYP2C9 CYP2D6
9 monoterpenoid metabolic process GO:0016098 8.62 CYP2C9 CYP2D6

Molecular functions related to Hepatitis D according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.32 CYP2C9 CYP2D6
2 drug binding GO:0008144 9.26 CYP2C9 CYP2D6
3 monooxygenase activity GO:0004497 9.16 CYP2C9 CYP2D6
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 8.96 CYP2C9 CYP2D6
5 steroid hydroxylase activity GO:0008395 8.62 CYP2C9 CYP2D6

Sources for Hepatitis D

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....